Research Article
Emergency Use of Tocilizumab in Moderate and Severe COVID-19 Patients over the Prevaccination Stage during the Pandemic in Mexico
Table 1
Basal characteristics of the population.
| Age (years) | 49 ± 11.9 | Man% | 58.6 | Woman% | 41.4 | Days from onset | 8.49 ± 6.91 | BMI kg/m2 | 29.2 ± 5.02 |
| Comorbidities | Asthma % | 2.9 | Diabetes mellitus % | 21.4 | COPD % | 1.4 | Obesity % | 31.4 | Hypertension % | 22.9 | CKD % | 1.4 | Smoking % | 2.9 |
| Vital signs at admission | SaO2% without O2 | 73.46 ± 12.96 | SaO2% with O2 | 87.09 ± 8.38 | Heart rate | 92 ± 16.66 | Respiratory rate | 23.9 ± 4.60 |
| CO-RADS % | 3 | 8.6 | 4 | 32.9 | 5 | 58.6 | Respiratory support % | 31.4 |
| Test values | Leucocytes ×103/uL | 10−3 ± 4.70 | Neutrophils ×103/uL | 9.0 ± 4.65 | Lymphocytes ×103/uL | 0.85 ± 0.50 | Glucose mg/dL | 152 ± 103.09 | ALT mg/dL | 59.23 ± 82.77 | AST g/dL | 67.10 ± 128.50 | LDH mg/dL | 493.57 ± 286.22 | Bilirubin total mg/dL | 0.63 ± 0.35 | CK mg/dl | 109.91 ± 103.79 | GFR | 88.63 ± 30.22 | Fibrinogen mg/dL | 1358 ± 2451.69 | PCR | 20.60 (±11.74 |
| Other drugs | Hydroxychloroquine | 11.4 | Azithromycin | 4.3 | Clarithromycin | 94.3 | Enoxaparin | 100 | Oseltamivir | 22.9 | Steroids | 70 | Lopinavir/Ritonavir | 15.7 |
|
|